title: Purified protein derivative reaction in systemic lupus erythematosus patients. Indirect study of cellular immunity.
abstract: Cutaneous anergy in SLE patients results from disease activity and/or immunosuppressive treatment (IT). The aim of this study was to evaluate purified protein derivative (PPD) reaction in SLE patients. A total of 145 patients and 20 controls were studied. Five units of PPD were applied on day 0, and skin reaction was measured after 3 (PPD1) and 6 (PPD2) days. A booster was applied (day 14), and the reaction was measured after 3 (PPD3) and 6 (PPD4) days. Non-parametric ANOVA test and unpaired Student's t-test were performed. Forty patients (group I) were inactive (MexSLEDAI < 3), receiving no IT (at least 3 months previous to the PPD test); 39 (group II) were inactive receiving IT; 24 (group III) were active without IT, and 42 (group IV) were active with IT. Active patients had lower PPD1 (group III, 1.4 +/- 0.9; group IV, 0.6 +/- 0.5) than inactive patients (group I, 8.4 +/- 2.3; group II, 5.1 +/- 1.9) and than controls (9.4 +/- 3; P < or = 0.001). Group IV had lower delayed response (PPD2 = 0.3 +/- 0.3) than inactive groups (group I, 2.6 +/- 0.9; group II, 3.1 +/- 0.8) and than controls (7.9 +/- 2.5; P < or = 0.001). Group III had lower delayed reaction (PPD2 = 1.2 +/- 0.8) than controls (P < or = 0.001). Active SLE patients, receiving or not receiving IT, had lower skin response to PPD than inactive patients and controls.
authors.affiliation: Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, México.
authors.forename: V
authors.initials: V
authors.lastname: Pascual-Ramos
authors.forename: B
authors.initials: B
authors.lastname: Hernández-Cruz
authors.forename: I
authors.initials: I
authors.lastname: Villalobos
authors.forename: J
authors.initials: J
authors.lastname: Sifuentes-Osornio
authors.forename: J
authors.initials: J
authors.lastname: Alcocer-Varela
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology*; D007271:Injections, Intradermal; D008180:Lupus Erythematosus, Systemic / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D012867:Skin / Q000276:immunology; D014373:Tuberculin / Q000008:administration & dosage* / Q000276:immunology
chemical_list: D014373:Tuberculin